|
|
Vaccine Detail
|
MVA/S vaccine |
| Vaccine Information |
- Vaccine Name: MVA/S vaccine
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: S protein (Bisht et al., 2004)
- S protein gene of SARS-CoV
gene engineering:
- Type: Recombinant vector construction
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: Recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S (Bisht et al., 2004)
|
| Host Response |
|
Mouse Response
- Host Strain: Balb/c(Bisht et al., 2004)
- Vaccination Protocol: Mice were inoculated i.n. or i.m. with 10^7 pfu of MVA/S at time 0 and again at 4 weeks. (Bisht et al., 2004)
- Immune Response: Antibodies neturalized SARS-CoV in vitro after 2 doses (Bisht et al., 2004)
- Challenge Protocol: inoculated intranasally or intramuscularly with 7log pfu of MVA at 0 and 4 weeks then challenged with TCID50 of SARS-CoV (Bisht et al., 2004)
- Efficacy: little to no replication of SARS-CoV in the respiratory tracts after internasal inoculation(Bisht et al., 2004)
|
| References |
Bisht et al., 2004: Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(17); 6641-6646. [PubMed: 15096611].
|
|
